Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559935 | 1.00 | BACE1 (0.40) | BACE1KDM4EALDH1A1KMT2ANOTUM | |
| SCHEMBL10748633 | 0.82 | XPO1 (0.41) | KDM4EALDH1A1NOTUMMAPTGLP1R | |
| SCHEMBL25696362 | 0.78 | NOS2 (0.37) | BACE1KMT2AMAPTMEN1NPC1 | |
| SCHEMBL14744273 | 0.76 | BACE1 (0.45) | BACE1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL30063182 | 0.76 | BACE1 (0.41) | BACE1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL9106225 | 0.74 | ENPP1 (0.39) | KDM4ENOTUMGLP1RENPP3ENPP1 | |
| SCHEMBL9607760 | 0.74 | NOS3 (0.52) | BACE1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL1256440 | 0.74 | BACE1 (0.40) | BACE1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL21861634 | 0.74 | BACE1 (0.40) | BACE1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL16028855 | 0.74 | BACE1 (0.40) | BACE1KDM4EALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117881664-A | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as NAV1.8 inhibitors | 默沙东有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4334293-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2021249417-A1 | HETEROCYCLIC COMPOUND AND DERIVATIVE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2021-12-16 | — | — | WO | disclosed |
| CN-113613646-A | Histone acetyltransferase modulators and compositions and uses thereof | 纽约市哥伦比亚大学理事会 | 2021-11-05 | — | — | CN | disclosed |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3797101-A1 | PYRIDIDNE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| CN-112390745-A | Pyridine nicotinamide derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-02-23 | — | — | CN | disclosed |
| CN-112368274-A | Pyridine-sulfonamide derivatives as sodium channel inhibitors | 豪夫迈·罗氏有限公司 | 2021-02-12 | — | — | CN | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020163731-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND COMPOSITIONS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2017173965-A1 | NOVEL URAT1 INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 江苏新元素医药科技有限公司 | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | BACE1 2597/4885KDM4E 3576/4885ALDH1A1 1459/4885 |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | BACE1 121/4885KDM4E 3923/4885ALDH1A1 653/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | BACE1 121/4885KDM4E 3923/4885ALDH1A1 653/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | BACE1 4518/4885KDM4E 2913/4885ALDH1A1 3178/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | BACE1 1068/4885KDM4E 4178/4885ALDH1A1 3094/4885 |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | SCN1B, CACNA1A, SCN1A | BACE1 3202/4885KDM4E 1990/4885ALDH1A1 3192/4885 |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, CACNA1A, SCN1A | BACE1 3115/4885KDM4E 2108/4885ALDH1A1 3086/4885 |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | F12, REN, ZYX | BACE1 880/4885KDM4E 3360/4885ALDH1A1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.